Recommendations for probiotic use-2011 update.

Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06150, USA.
Journal of clinical gastroenterology (Impact Factor: 2.21). 11/2011; 45 Suppl:S168-71. DOI: 10.1097/MCG.0b013e318230928b
Source: PubMed

ABSTRACT This study describes the consensus opinion of the participants of the third Yale Workshop on probiotic use. There were 10 experts participating. The recommendations update those of the first 2 meetings that were published in 2005 and 2008. The workshop presentations and papers in this supplement relate to the involvement of normal microbiota involved in intestinal microecology, how the microbes interact with the intestine to affect our immunologic responses, the stability and natural history of probiotic organisms, and the role of the intestinal microbatome with regard to affecting cardiac risk factors and obesity. Recommendations for the use of probiotics in necrotizing enterocolitis, childhood diarrhea, inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile diarrhea are reviewed. As in previous publications, the recommendations are given as A, B, or C ratings. The recent positive experiences with bacteriotherapy (fecal microbiome transplant) are also discussed in detail and a positive recommendation is made for use in severe resistant C. difficile diarrhea.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim was to evaluate the effects of orally administered Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the number of salivary mutans streptococci (MS), amount of plaque, gingival inflammation and the oral microbiota in healthy young adults. The study was a randomised, controlled, double-blind trial. Healthy volunteers used lozenges containing a combination of LGG and BB-12 (test group, n = 29) or lozenges without added probiotics (control group, n = 31) for 4 weeks. At baseline and at the end of the test period, the plaque index (PI) and gingival index (GI) were determined, and stimulated saliva was collected. The microbial composition of saliva was assessed using human oral microbe identification microarray (n = 30). MS and lactobacilli (LB) were plate cultured. The probiotic lozenge decreased both PI and GI (p < 0.05) while no changes were observed in the control group. However, no probiotic-induced changes were found in the microbial compositions of saliva in either group. The probiotic lozenge improved the periodontal status without affecting the oral microbiota. Short-term consumption of LGG and BB-12 decreased the amount of plaque which was associated with a clinical impact: a decrease in gingival inflammation.
    Clinical Oral Investigations 03/2014; · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Guidelines consider certain probiotics useful in the management of acute gastroenteritis. This study evaluated the use of Lactobacillus (L) reuteri DSM 17938. A multicenter, randomised, single blind, clinical trial was performed in hospitalised children with acute gastroenteritis lasting 12 to 72 hours. Children received conventional therapy with, or without, 1x10(8) CFU of L reuteri DSM 17938 for five days. The primary endpoint was the duration of diarrhoea and secondary outcomes were days of hospitalisation and the percentage of children with diarrhoea after each day of treatment. We compared 64 children receiving L reuteri group with 63 controls. L reuteri reduced the duration of diarrhoea after 24 hours (p<0.001) and more diarrhoea-free children were seen in the L reuteri than control group after 24 and 48 hours (50% versus 5%, p<0.001) and 72 hours (69% versus 11%, p<0.001). L reuteri reduced mean hospital stays (4.31 ± 1.3 days versus 5.46 ± 1.77 days, p<0.001). Prolonged diarrhoea occurred in 17% of the controls, but none of the L reuteri group. No adverse effects were reported. L reuteri effectively reduced the duration of acute diarrhoea and hospital stays in children hospitalised with acute gastroenteritis. Outpatient data is now required. This article is protected by copyright. All rights reserved.
    Acta Paediatrica 03/2014; · 1.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Probiotics are microorganisms exerting beneficial effects on the host. They can be ingested through foods or supplements and their inclusion in these products is regulated in Canada by the Health Canada Health Products and Food Branch. The aim of this article is to summarize current evidence from randomized controlled trials and guidelines from Health Canada, the World Health Organization, and internationally recognized expert committees in the hope that it will help practitioners and professionals recommending probiotics to healthy and diseased patients, with a focus on the Canadian setting. From a general perspective, probiotics can be recommended for prevention of diseases that are associated to altered intestinal ecology. Specifically, they can be recommended for prevention of upper respiratory tract infections and pouchitis, for prevention and management of necrotizing enterocolitis, bacterial vaginosis and antibiotic associated diarrhea, including Clostridium difficile infection, and for treatment of atopic eczema in cow's milk allergy and of infectious diarrhea. Additional substantiated probiotic benefits include prevention of hypercholesterolemia, management of constipation, reduction of recurrent urinary tract infections, improvement of irritable bowel syndrome symptoms, and reduction of antibiotics side effects in Helicobacter pylori eradication. Because probiotics are generally recognized as safe and can be removed with antimicrobial agents, their use should be considered in patients of all ages.
    Applied Physiology Nutrition and Metabolism 05/2014; · 2.01 Impact Factor


Available from
Jun 1, 2014